DOXERCALCIFEROL injection, solution

Doxercalciferol by

Drug Labeling and Warnings

Doxercalciferol by is a Prescription medication manufactured, distributed, or labeled by Eugia US LLC, Eugia Pharma Specialities Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    • Doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) on dialysis.
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Prior to Initiation of Doxercalciferol Injection

    • Ensure serum calcium is not above the upper limit of normal before initiating treatment with doxercalciferol injection [see Warnings and Precautions (5.1)].

    2.4 Important Administration Instructions for Doxercalciferol Injection

    • Administer doxercalciferol injection intravenously as a bolus dose at the end of dialysis.
    • Inspect doxercalciferol injection visually prior to administration; the solution should appear clear and colorless. Do not use if the solution is not clear or particles are present.
    • After initial vial use:
      • discard unused portion of the single-dose vial;
      • store opened multiple-dose vial for up to 3 days at 2°C to 8°C (36°F to 46°F). Discard unused portion of multiple-dose vial after 3 days [see How Supplied/Storage and Handling (16)].

    2.5 Dosage Recommendations for Doxercalciferol Injection in Patients with CKD on Dialysis

    • Initiate doxercalciferol injection at a dose of 4 mcg given by bolus intravenous administration three times weekly at the end of dialysis (no more frequently than every other day).
    • Target the maintenance dose of doxercalciferol injection to intact parathyroid hormone (PTH) levels within the desired therapeutic range and serum calcium within normal limits.
    • Monitor serum calcium, phosphorus, and intact PTH levels weekly after initiation of therapy or dose adjustment.
    • Titrate the dose of doxercalciferol injection based on intact PTH. The dose may be increased at 8-week intervals by 1 mcg to 2 mcg if intact PTH is not lowered by 50% and fails to reach the target range. The maximum dose is 18 mcg weekly. Prior to raising the dose, ensure serum calcium is within normal limits.
    • Suspend or decrease the dose if intact PTH is persistently and abnormally low to reduce the risk of adynamic bone disease [see Warnings and Precautions (5.4)] or if serum calcium is consistently above the normal range to reduce the risk of hypercalcemia [see Warnings and Precautions (5.1)]. If suspended, the drug should be restarted one week later at a dose that is at least 1 mcg lower.

    2.6 Drug Interactions that May Require Dosage Adjustments of Doxercalciferol Injection

    • Increased monitoring of serum calcium and dose adjustment of doxercalciferol injection may be necessary when given concomitantly with drugs that may increase the risk of hypercalcemia [see Drug Interactions (7)].
    • Increased monitoring of both serum calcium and intact PTH as well as dose adjustment of doxercalciferol injection may be necessary when given concomitantly with cytochrome P450 inhibitors or enzyme inducers [see Drug Interactions (7)].
  • 3 DOSAGE FORMS AND STRENGTHS

    Injection: clear and colorless aqueous solution available as follows:

    • 2 mcg per mL single-dose vial
    • 4 mcg per 2 mL (2 mcg/mL) single-dose vial
    • 4 mcg per 2 mL (2 mcg/mL) multiple-dose vial
  • 4 CONTRAINDICATIONS

    Doxercalciferol is contraindicated in patients with:

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypercalcemia

    Hypercalcemia may occur during doxercalciferol treatment. Acute hypercalcemia may increase the risk of cardiac arrhythmias and seizures and may potentiate the effect of digitalis on the heart [see Warnings and Precautions (5.2)]. Chronic hypercalcemia can lead to generalized vascular calcification and other soft-tissue calcification. Severe hypercalcemia may require emergency attention.


    Hypercalcemia may be exacerbated by concomitant administration of high doses of calcium-containing preparations, thiazide diuretics, or other vitamin D compounds [see Drug Interactions (7)]. In addition, high intake of calcium and phosphate concomitantly with vitamin D compounds may lead to hypercalciuria and hyperphosphatemia. Patients with a history of hypercalcemia prior to initiating therapy may be at increased risk for development of hypercalcemia with doxercalciferol. In these circumstances, frequent serum calcium monitoring and doxercalciferol dose adjustments may be required.


    When initiating doxercalciferol or adjusting doxercalciferol dose, measure serum calcium frequently (weekly in patients with CKD on dialysis). Once a maintenance dose has been established, measure serum calcium monthly for 3 months and then every 3 months. If hypercalcemia occurs, reduce the dose or discontinue doxercalciferol until serum calcium is normal [see Dosage and Administration (2)].


    Inform patients about the symptoms of elevated calcium (feeling tired, difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination and weight loss) and instruct them to report new or worsening symptoms when they occur.

    5.2 Digitalis Toxicity

    Doxercalciferol can cause hypercalcemia [see Warnings and Precautions (5.1)] which increases the risk of digitalis toxicity. In patients using doxercalciferol concomitantly with digitalis compounds, monitor both serum calcium and patients for signs and symptoms of digitalis toxicity. Increase the frequency of monitoring when initiating or adjusting the dose of doxercalciferol [see Drug Interactions (7)].

    5.3 Serious Hypersensitivity Reactions

    Serious hypersensitivity reactions, including fatal outcome, have been reported post marketing in patients on hemodialysis following administration of doxercalciferol injection. Hypersensitivity reactions include anaphylaxis with symptoms of angioedema (involving face, lips, tongue and airways), hypotension, unresponsiveness, chest discomfort, shortness of breath, and cardiopulmonary arrest. These reactions may occur separately or together.

    Monitor patients receiving doxercalciferol upon initiation of treatment for hypersensitivity reactions. Should a hypersensitivity reaction occur, discontinue doxercalciferol, monitor and treat if indicated [see Contraindications (4)].

    5.4 Adynamic Bone Disease

    Adynamic bone disease with subsequent increased risk of fractures may develop if intact PTH levels are suppressed by doxercalciferol to abnormally low levels. Monitor intact PTH levels to avoid oversuppression and adjust the doxercalciferol dose, if needed [see Dosage and Administration (2)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed in greater detail in another section of the label:

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Doxercalciferol Capsules
    Adverse reactions in patients with CKD on dialysis

    Doxercalciferol capsules have been evaluated in two placebo-controlled, double-blind studies in patients with CKD on hemodialysis. Patients were treated with doxercalciferol capsules (n=61) or placebo (n=61). After randomization to two groups, eligible patients underwent an 8-week washout period during which no vitamin D derivatives were administered to either group. Subsequently, all patients received doxercalciferol capsules in an open-label fashion for 16 weeks followed by a double-blind period of 8 weeks during which patients received either doxercalciferol capsules or placebo. Adverse reactions occurring in the doxercalciferol capsule groups at a frequency of 2% or greater, and more frequently than in the placebo group are presented in Table 2.

    Table 2: Adverse Reactions Occurring in ≥2% Doxercalciferol Capsule-Treated Patients with CKD on Dialysis and Greater than Placebo in Two Double-Blind Clinical Studies    
    * A patient who reported the same medical term more than once was counted only once for that medical term.   
    Adverse Reaction*
    		Doxercalciferol (n=61)
    %
    		Placebo (n=61)
    %
    Edema
    		34
    		21
    Malaise
    		28
    		20
    Headache
    		28
    		18
    Nausea/Vomiting
    		21
    		20
    Dizziness
    		12
    		10
    Dyspnea
    		12
    		7
    Pruritus
    		8
    		7
    Bradycardia
    		7
    		5
    Anorexia
    		5
    		3
    Dyspepsia
    		5
    		2
    Arthralgia
    		5
    		0
    Weight increase
    		5
    		0
    Abscess
    		3
    		0
    Sleep disorder
    		3
    		0

    Doxercalciferol Injection
    Adverse reactions in patients with CKD on hemodialysis

    Doxercalciferol injection has been studied in 70 patients with CKD on hemodialysis in two 12-week, open-label, single-arm, multicenter studies [see Clinical Studies (14.3)]. The incidence of hypercalcemia and hyperphosphatemia increased during therapy with doxercalciferol injection. Patients with higher pretreatment serum levels of calcium (>10.5 mg/dL) or phosphorus (>6.9 mg/dL) were more likely to experience hypercalcemia or hyperphosphatemia.

    There was no placebo group included in the studies of doxercalciferol injection. Adverse reactions in patients with CKD on hemodialysis receiving doxercalciferol injection are expected to be similar to those reported in placebo-controlled studies of doxercalciferol capsules presented in Table 2.

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during postapproval use of doxercalciferol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.

    Hypersensitivity reactions, including fatal outcome, have been reported in patients on hemodialysis following administration of doxercalciferol injection. Hypersensitivity reactions include anaphylaxis with symptoms of angioedema (involving face, lips, tongue and airways), hypotension, unresponsiveness, chest discomfort, shortness of breath, cardiopulmonary arrest, pruritus, and skin burning sensation.

  • 7 DRUG INTERACTIONS

    Table 3 includes clinically significant drug interactions with doxercalciferol. 

    Table 3: Clinically Significant Drug Interactions with Doxercalciferol Injection    
    Drugs that May Increase the Risk of Hypercalcemia
    Clinical Impact
    		Concomitant administration of high doses of calcium-containing preparations or other vitamin D compounds may increase the risk of hypercalcemia. Thiazide diuretics are known to induce hypercalcemia by reducing excretion of calcium in the urine.
    Examples
    		Calcium-containing products, other vitamin D compounds or thiazide diuretics
    Intervention
    		Monitor serum calcium concentrations more frequently and adjust doxercalciferol dose as needed [see Warnings and Precautions (5.1)].
    Digitalis Compounds
    Clinical Impact
    		Doxercalciferol can cause hypercalcemia which can potentiate the risk of digitalis toxicity.
    Intervention
    		Monitor patients for signs and symptoms of digitalis toxicity and increase frequency of serum calcium monitoring when initiating or adjusting the dose of doxercalciferol in patients receiving digitalis compounds [see Warnings and Precautions (5.2)].
    Cytochrome P450 Inhibitors
    Clinical Impact
    		Doxercalciferol is activated by CYP 27 in the liver. Cytochrome P450 inhibitors may inhibit the 25-hydroxylation of doxercalciferol and thus reduce the formation of active doxercalciferol moiety [see Clinical Pharmacology (12.3)].
    Examples
    		Ketoconazole and erythromycin
    Intervention
    		If a patient initiates or discontinues therapy with a cytochrome P450 inhibitor, dose adjustment of doxercalciferol may be necessary. Monitor intact PTH and serum calcium concentrations closely.
    Enzyme Inducers
    Clinical Impact
    		Doxercalciferol is activated by CYP 27 in the liver. Enzyme inducers may affect the 25-hydroxylation of doxercalciferol [see Clinical Pharmacology (12.3)].
    Examples
    		Glutethimide and phenobarbital
    Intervention
    		If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. Monitor intact PTH and serum calcium concentrations closely.
    Magnesium-containing Products
    Clinical Impact
    		Concomitant administration of doxercalciferol and high doses of magnesium-containing products may increase the risk of hypermagnesemia.
    Examples
    		Magnesium-containing products such as antacids
    Intervention
    		Avoid use of magnesium-containing products and doxercalciferol in patients on chronic renal dialysis.
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary
    The limited available data with doxercalciferol in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see Clinical Considerations]. In reproduction studies in rats and rabbits administered doxercalciferol during organogenesis at up to 20 mcg/kg/day and 0.1 mcg/kg/day, respectively (approximately 25 times (rats) and less than (rabbits) the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area), no adverse developmental effects were observed [see Data].

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    Clinical Considerations

    Disease-associated maternal and/or embryo/fetal risk

    Chronic kidney disease in pregnancy increases the risk for maternal hypertension and preeclampsia, miscarriage, preterm delivery polyhydramnios, stillbirth, and low-birth-weight infants.

    Data

    Animal data

    There were no adverse effects on fetal development when doxercalciferol was administered at doses up to 20 mcg/kg/day in pregnant rats or doses up to 0.1 mcg/kg/day in pregnant rabbits during the period of organogenesis.

    8.2 Lactation

    Risk Summary
    There is no information available on the presence of doxercalciferol in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Infants exposed to doxercalciferol through breast milk should be monitored for signs and symptoms of hypercalcemia [see Clinical Considerations].

    The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for doxercalciferol and any potential adverse effects on the breastfed child from doxercalciferol or from the underlying maternal condition.

    Clinical Considerations

    Infants exposed to doxercalciferol injection through breast milk should be monitored for signs and symptoms of hypercalcemia, including seizures, vomiting, constipation and weight loss. Monitoring of serum calcium in the infant should be considered.

    8.4 Pediatric Use

    Safety and efficacy of doxercalciferol in pediatric patients have not been established.

    8.5 Geriatric Use

    Clinical studies of doxercalciferol did not include sufficient numbers of patients 65 years or over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or cardiac function, and of concomitant disease or other drug therapy.

    8.6 Hepatic Impairment

    Patients with hepatic impairment may not metabolize doxercalciferol appropriately. More frequent monitoring of intact PTH, calcium, and phosphorus levels should be done in patients with hepatic impairment.

  • 10 OVERDOSAGE

    Overdosage of doxercalciferol may lead to hypercalcemia, hypercalciuria, and hyperphosphatemia [see Warnings and Precautions (5.1)]. The treatment of acute overdosage should consist of supportive measures and discontinuation of doxercalciferol administration. Serum calcium levels should be measured until normal.

    Based on similarities between doxercalciferol and its active metabolite, 1α,25-(OH)2D2, it is expected that doxercalciferol is not removed from the blood by dialysis.

  • 11 DESCRIPTION

    Doxercalciferol injection contains doxercalciferol, which is a synthetic vitamin D2 analog. Doxercalciferol undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2.

    Doxercalciferol, USP is a white to off-white crystallized powder with a calculated molecular weight of 412.66 and a molecular formula of C28H44O2. It is soluble in oils and organic solvents, but is relatively insoluble in water. Chemically, doxercalciferol is (1α,3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol. The structural formula is:
    Chemical Structure
    Injection
    Doxercalciferol injection 1 mL single-dose vials contain 2 mcg/mL of doxercalciferol. Doxercalciferol injection 2 mL single-dose vials contain 4 mcg/2 mL (2 mcg/mL) of doxercalciferol. Each milliliter (mL) of solution contains 2 mcg doxercalciferol and the following inactive ingredients: butylated hydroxytoluene (0.02 mg); disodium edetate (1.1 mg); ethanol, 100% (0.05 mL); polysorbate 20 (10 mg); sodium chloride (1.5 mg); sodium phosphate dibasic, heptahydrate (14.4 mg); and sodium phosphate monobasic, monohydrate (1.8 mg).

    Doxercalciferol injection 2 mL multiple-dose vials contain 4 mcg/2 mL (2 mcg/mL) of doxercalciferol. Each milliliter (mL) of solution contains 2 mcg doxercalciferol and the following inactive ingredients: butylated hydroxytoluene (0.02 mg); disodium edetate (1.1 mg); ethanol, 100% (0.075 mL); polysorbate 20 (10 mg); sodium chloride (1.5 mg); sodium phosphate dibasic, heptahydrate (14.4 mg); and sodium phosphate monobasic, monohydrate (1.8 mg).

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Doxercalciferol is a synthetic vitamin D2 analog that requires metabolic activation to form the active 1α,25-(OH)2D2 metabolite, which binds to the vitamin D receptor (VDR) to result in the selective activation of vitamin D responsive pathways. Vitamin D and doxercalciferol have been shown to reduce PTH levels by inhibiting PTH synthesis and secretion.

    12.3 Pharmacokinetics

    Absorption
    In healthy volunteers, peak blood levels of 1α,25-(OH)2D2, the major metabolite of doxercalciferol, are attained at 8 hours after a single intravenous dose of doxercalciferol.

    Elimination
    The mean elimination half-life of 1α,25-(OH)2D2 after an oral dose is approximately 32 to 37 hours with a range of up to 96 hours.

    Metabolism

    Doxercalciferol is activated by CYP 27 in the liver to form 1α,25-(OH)2D2 (major metabolite) and 1α,24-dihydroxyvitamin D2 (minor metabolite). Activation of doxercalciferol does not require the involvement of the kidneys.

    Specific Populations
    Patients with renal impairment

    The mean elimination half-life of 1α,25-(OH)2D2 in patients with end-stage renal disease (ESRD) and in healthy volunteers appears to be similar following an oral dose. Hemodialysis causes a temporary increase in 1α,25- (OH)2D2 mean concentrations, presumably due to volume contraction. 1α,25-(OH)2D2 is not removed from blood during hemodialysis.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    In a 104-week carcinogenicity study in rats, there was an increased incidence of benign and malignant adrenal pheochromocytomas in both males and females at oral doses of 0.04, 0.13, and 0.39 mcg/kg/day (less than the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area). This increased incidence of pheochromocytomas in rats may be due to altered calcium homeostasis by doxercalciferol. No evidence of genetic toxicity was observed in an in vitro bacterial mutagenicity assay (Ames test) or a mouse lymphoma gene mutation assay. Doxercalciferol caused structural chromatid and chromosome aberrations in an in vitro human lymphocyte clastogenicity assay with metabolic activation. However, doxercalciferol was negative in an in vivo mouse micronucleus clastogenicity assay.

    Doxercalciferol had no effect on male or female fertility in rats at oral doses up to 2.5 mcg/kg/day (approximately 3 times the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area).

  • 14 CLINICAL STUDIES

    14.3 Clinical Studies of Doxercalciferol Injection in Patients with CKD on Dialysis

    The safety and effectiveness of Doxercalciferol injection were evaluated in two open-label, single-arm, multicenter clinical studies (Study C and Study D) in a total of 70 patients with CKD on hemodialysis. Patients in Study C were an average age of 54 years (range: 23 to 73), were 50% male, and were 61% African- American, 25% Caucasian, and 14% Hispanic, and had been on hemodialysis for an average of 65 months. Patients in Study D were an average age of 51 years (range: 28 to 76), were 48% male, and 100% African-American and had been on hemodialysis for an average of 61 months. This group of 70 of the 138 patients who had been treated with doxercalciferol capsules in prior clinical studies (Study A and Study B) received doxercalciferol injection in an open-label fashion for 12 weeks following an 8-week washout (control) period. Dosing of doxercalciferol injection was initiated at the rate of 4 mcg administered at the end of each dialysis session (3 times weekly) for a total of 12 mcg per week. The dosage of doxercalciferol was adjusted to achieve intact PTH levels (measured weekly) within a targeted range of 150 pg/mL to 300 pg/mL. The dosage was increased by 2 mcg per dialysis session after 8 weeks of treatment if the intact PTH levels remained above 300 pg/mL and were greater than 50% of baseline levels. The maximum dosage was limited to 18 mcg per week. If at any time during the study intact PTH fell below 150 pg/mL, doxercalciferol injection was immediately suspended and restarted at a lower dosage the following week. Mean weekly doses ranged from 9 mcg to 13 mcg in Study C and ranged from 9 mcg to 12 mcg in Study D.

    Fifty-two (74%) of the 70 patients who were treated with doxercalciferol injection achieved intact PTH levels ≤300 pg/mL. Forty-one (59%) of these patients exhibited plasma intact PTH levels ≤300 pg/mL on at least 3 occasions. Thirty-six (51%) patients had plasma intact PTH levels <150 pg/mL on at least one occasion during study participation. Decreases in plasma intact PTH from baseline values were calculated using as baseline the average of the last 3 values obtained during the 8-week washout period and are displayed in Table 6.

    Table 6: Intact PTH Summary Data for Patients with CKD on Dialysis Receiving Doxercalciferol Injection in Studies C and D   
    * Values were carried forward for the two patients on study for 10 weeks
    † Treatment intact PTH minus baseline intact PTH
    ‡ Wilcoxon one-sample test   
    Intact PTH Level
    		Study C
    (n=28)
    		Study D
    (n=42)
    		Combined Protocols
    (n=70)
    Baseline (Mean of Weeks -2, -1, and 0)
    Mean (SE)
    		698 (60)
    		762 (65)
    		736 (46)
    Median
    		562
    		648
    		634
    On-treatment (Week 12*)
    Mean (SE)
    		406 (63)
    		426 (60)
    		418 (43)
    Median
    		311
    		292
    		292
    Change from Baseline†
    Mean (SE)
    		-292 (55)
    		-336 (41)
    		-318 (33)
    Median
    		-274
    		-315
    		-304
    P-value‡
    		0.004
    		0.001
    		<0.001

    Doxercalciferol treatment resulted in at least 30% reduction from baseline in mean intact PTH levels during the 12-week open-label treatment period in more than 92% of the 70 treated patients.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied
    Doxercalciferol injection is a clear, colorless aqueous solution supplied in 2 mL amber glass vials as follows.

    Total Strength per Total Volume
    		Strength per mL
    		Flip-off Cap Color
    		Vial Count per Carton × Total Vial Volume and vial Type
    		Carton NDC
    		Vial NDC
    2 mcg per mL
    		2 mcg/mL
    		Yellow
    		1 × 1 mL single-dose vial
    		55150-357-01
    		55150-357-01
    50 × 1 mL single-dose vials
    		55150-357-50
    4 mcg per 2 mL
    		2 mcg/mL
    		Sky blue
    		1 × 2 mL single-dose vial
    		55150-358-01
    		55150-358-01
    50 × 2 mL single-dose vials
    		55150-358-50
    4 mcg per 2 mL
    		2 mcg/mL
    		Magenta
    		1 × 2 mL multiple-dose vial
    		55150-359-01
    		55150-359-01
    50 × 2 mL multiple-dose vials
    		55150-359-50

    Storage and Handling

    *Protect from light. Store unopened vial in original carton.  
    Dosage Form
    		Storage temperature
    		Excursions permitted to
    		In-use storage
    Single-dose vial*
    		25°C (77°F)
    		15°C to 30°C (59°F to 86°F)
    [see USP controlled room temperature]
    		Discard unused portion
    Multiple-dose vial*
    		25°C (77°F)
    		15°C to 30°C (59°F to 86°F)
    [see USP controlled room temperature]
    		2°C to 8°C (36°F to 46°F),
    Discard 3 days after opening

    The vial stopper is not made with natural rubber latex.

  • 17 PATIENT COUNSELING INFORMATION

    Hypercalcemia
    Advise patients to contact a health care provider if they develop symptoms of elevated calcium (e.g. feeling tired, difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination and weight loss) [see Warnings and Precautions (5.1)].

    Hypersensitivity
    Inform patients that hypersensitivity reactions can occur with doxercalciferol [see Warnings and Precautions (5.3)].

    Monitoring
    Inform patients that they will need routine monitoring of laboratory parameters such as calcium and intact PTH while receiving doxercalciferol. Inform patients that more frequent monitoring is necessary during the initiation of therapy, following dose changes or when potentially interacting medications are started or discontinued [see Dosage and Administration (2), Drug Interactions (7)].

    Drug Interactions
    Advise patients to inform their physician of all medications, including prescription and nonprescription drugs, and supplements they are taking. Advise patients to also inform their physician that they are receiving doxercalciferol if a new medication is prescribed [see Drug Interactions (7)].

    Distributed by:
    Eugia US LLC
    279 Princeton-Hightstown Rd.
    E. Windsor, NJ 08520

    Manufactured by:
    Eugia Pharma Specialities Limited
    Hyderabad - 500032
    India

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-2 mcg per mL - Container Label

    Rx only                   NDC 55150-357-01
    Doxercalciferol
    Injection
    2 mcg per mL
    For Intravenous Use Only
    1 mL Single-Dose Vial
    Discard unused portion


    PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-2 mcg per mL - Container Label
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-2 mcg per mL - Container-Carton (1 Vial)

    Rx only                   NDC 55150-357-01
    Doxercalciferol
    Injection
    2 mcg per mL
    For Intravenous Use Only
    Contains Alcohol 5% (v/v)
    One 1 mL Single-Dose Vial
    Discard unused portion
    eugia


    doxercalciferol-figure-2

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-2 mcg per mL - Container-Carton (50 Vials)

    Rx only                   NDC 55150-357-50
    Doxercalciferol
    Injection
    2 mcg per mL
    For Intravenous Use Only
    Contains Alcohol 5% (v/v)
    50 x 1 mL Single-Dose Vials
    Discard unused portion
    eugia


    doxercalciferol-figure-3

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-4 mcg per 2 mL (2 mcg/mL) (SDV) - Container Label

    Rx only                   NDC 55150-358-01
    Doxercalciferol
    Injection
    4 mcg per 2 mL
    (2 mcg/mL)
    For Intravenous Use Only
    2 mL Single-Dose Vial
    Discard unused portion


    PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-4 mcg per 2 mL (2 mcg/mL) - Container Label
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-4 mcg per 2 mL (2 mcg/mL) (SDV) - Container-Carton (1 Vial)

    Rx only                   NDC 55150-358-01
    Doxercalciferol
    Injection
    4 mcg per 2 mL
    (2 mcg/mL)
    For Intravenous Use Only
    Contains Alcohol 5% (v/v)
    One 2 mL Single-Dose Vial
    Discard unused portion
    eugia


    doxercalciferol-figure-5

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-4 mcg per 2 mL (2 mcg/mL) (SDV) - Container-Carton (50 Vials)

    Rx only                   NDC 55150-358-50
    Doxercalciferol
    Injection
    4 mcg per 2 mL
    (2 mcg/mL)
    For Intravenous Use Only
    Contains Alcohol 5% (v/v)
    50 x 2 mL Single-Dose Vials
    Discard unused portion
    eugia


    doxercalciferol-figure-6

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-4 mcg per 2 mL (2 mcg/mL) (MDV) - Container Label

    Rx only                   NDC 55150-359-01
    Doxercalciferol
    Injection
    4 mcg per 2 mL
    (2 mcg/mL)
    For Intravenous Use Only
    2 mL Multiple-Dose Vial
    Discard vial 3 days after opening


    PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-4 mcg per 2 mL (2 mcg/mL) - Container Label
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-4 mcg per 2 mL (2 mcg/mL) (MDV) - Container-Carton (1 Vial)

    Rx only                   NDC 55150-359-01
    Doxercalciferol
    Injection
    4 mcg per 2 mL
    (2 mcg/mL)
    For Intravenous Use Only
    Contains Alcohol 7.5% (v/v)
    One 2 mL Multiple-Dose Vial
    Discard vial 3 days after opening
    eugia


    doxercalciferol-figure-8

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-4 mcg per 2 mL (2 mcg/mL) (MDV) - Container-Carton (50 Vials)

    Rx only                   NDC 55150-359-50
    Doxercalciferol
    Injection
    4 mcg per 2 mL
    (2 mcg/mL)
    For Intravenous Use Only
    Contains Alcohol 7.5% (v/v)
    50 x 2 mL Multiple-Dose Vials
    Discard vial 3 days after opening
    eugia


    doxercalciferol-figure-9

  • INGREDIENTS AND APPEARANCE
    DOXERCALCIFEROL 
    doxercalciferol injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 55150-357
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXERCALCIFEROL (UNII: 3DIZ9LF5Y9) (DOXERCALCIFEROL - UNII:3DIZ9LF5Y9) DOXERCALCIFEROL2 ug  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    ALCOHOL (UNII: 3K9958V90M)  
    POLYSORBATE 20 (UNII: 7T1F30V5YH)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE (UNII: 70WT22SF4B)  
    SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 55150-357-5050 in 1 CARTON01/24/2022
    1NDC: 55150-357-011 in 1 CARTON
    11 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21371701/24/2022
    DOXERCALCIFEROL 
    doxercalciferol injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 55150-358
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXERCALCIFEROL (UNII: 3DIZ9LF5Y9) (DOXERCALCIFEROL - UNII:3DIZ9LF5Y9) DOXERCALCIFEROL4 ug  in 2 mL
    Inactive Ingredients
    Ingredient NameStrength
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    ALCOHOL (UNII: 3K9958V90M)  
    POLYSORBATE 20 (UNII: 7T1F30V5YH)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE (UNII: 70WT22SF4B)  
    SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 55150-358-5050 in 1 CARTON01/24/2022
    1NDC: 55150-358-011 in 1 CARTON
    12 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21371701/24/2022
    DOXERCALCIFEROL 
    doxercalciferol injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 55150-359
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXERCALCIFEROL (UNII: 3DIZ9LF5Y9) (DOXERCALCIFEROL - UNII:3DIZ9LF5Y9) DOXERCALCIFEROL4 ug  in 2 mL
    Inactive Ingredients
    Ingredient NameStrength
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    ALCOHOL (UNII: 3K9958V90M)  
    POLYSORBATE 20 (UNII: 7T1F30V5YH)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE (UNII: 70WT22SF4B)  
    SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 55150-359-5050 in 1 CARTON01/24/2022
    1NDC: 55150-359-011 in 1 CARTON
    102 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21371701/24/2022
    Labeler - Eugia US LLC (968961354)
    Establishment
    NameAddressID/FEIBusiness Operations
    Eugia Pharma Specialities Limited650498244ANALYSIS(55150-357, 55150-358, 55150-359) , MANUFACTURE(55150-357, 55150-358, 55150-359) , PACK(55150-357, 55150-358, 55150-359)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.